Stijn L.W. Koolen
Erasmus University Medical Center
PharmacokineticsCancerInternal medicineOncologyChemistryAdverse effectLung cancerTamoxifenDosingPaclitaxelEndoxifenErlotinibNivolumabDocetaxelPopulationToxicityChromatographyCancer researchClinical trialMedicineArea under the curveGastroenterologyPharmacology
94Publications
13H-index
612Citations
Publications 100
Newest
Source
#1Nikki de Rouw (Radboud University Nijmegen)H-Index: 1
#2Hieronymus J. Derijks (Radboud University Nijmegen)H-Index: 3
Last. Lizza E.L. Hendriks (Maastricht University Medical Centre)H-Index: 21
view all 17 authors...
Pemetrexed is a cytotoxic drug for first-line treatment of lung cancer. It is often combined with other anticancer drugs such as cisplatin or carboplatin. In clinical practice, hyperhydration regimens are applied to overcome cisplatin-related nephrotoxicity. As pemetrexed is almost completely eliminated from the body by the kidneys, hyperhydration can result in augmented clearance. Furthermore, administration of large quantities of fluid may increase the volume of distribution of pemetrexed. Pha...
Source
#1Christi M.J. Steendam (EUR: Erasmus University Rotterdam)H-Index: 3
#2Robert Peric (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Stijn L.W. Koolen (EUR: Erasmus University Rotterdam)H-Index: 13
view all 15 authors...
Abstract null null Background null Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib in relapsed metastasized non-squamous (NSQ) non-small cell lung cancer (NSCLC). null null null Methods null Patients with relapsed Epidermal Growth Factor Receptor (EGFR) wild type (WT) NSQ-NSCLC were randomized 1:1 to docetaxel 75 mg/m2 intravenously ...
Source
#1Leni van Doorn (EUR: Erasmus University Rotterdam)H-Index: 9
#2Mandy M. van Rosmalen (EUR: Erasmus University Rotterdam)
Last. Peter de Bruijn (EUR: Erasmus University Rotterdam)H-Index: 27
view all 14 authors...
Chemotherapy-induced alopecia (CIA), a side effect with high impact, can be prevented by cooling the scalp during the administration of some cytotoxic drugs. However, the effects of this prolonged scalp cooling on the pharmacokinetics of chemotherapy have never been investigated. In this study, we compared the pharmacokinetics of the widely used chemotherapeutic agent paclitaxel (weekly dose of 80–100 mg/m2) in female patients with solid tumors using concomitant scalp cooling (n = 14) or not (n ...
Source
#1Florence Atrafi (EUR: Erasmus University Rotterdam)H-Index: 7
#2Ruben A.G. van Eerden (EUR: Erasmus University Rotterdam)H-Index: 4
Last. Jeffrey Damman (EUR: Erasmus University Rotterdam)H-Index: 7
view all 11 authors...
Docetaxel entrapped nanoparticle CPC634 is associated with dose-related skin toxicity that resembles conventional docetaxel (Cd)-related skin toxicity. This study compared the cutaneous pharmacokinetics and pharmacodynamics of docetaxel and CPC634. In this randomised cross-over study, patients with solid tumours received one cycle of CPC634 and Cd (both at 75 mg/m2). Skin biopsies were taken at baseline and at day 8 of both cycles. Released and total docetaxel (released docetaxel plus entrapped ...
Source
#1C Louwrens Braal (EUR: Erasmus University Rotterdam)H-Index: 2
#2Mei H. Lam (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Stijn L.W. Koolen (EUR: Erasmus University Rotterdam)H-Index: 13
view all 10 authors...
Abstract A reliable, specific, selective and robust liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was developed for the determination of ribociclib in both dried blood spot (DBS) samples and potassium EDTA plasma. DBS samples were obtained simultaneously with a plasma sample in advanced breast cancer patients treated with ribociclib. A 6 mm disk from the central part of the dried blood spot sample was punched, followed by extraction of ribociclib using liquid-liquid extraction...
Source
#4Wim J. R. Rietdijk (Erasmus University Medical Center)H-Index: 2
#7Ron H.J. Mathijssen (Erasmus University Medical Center)H-Index: 26
Oxycodone is frequently used for treating cancer-related pain, while not much is known about the factors that influence treatment outcomes in these patients. We aim to unravel these factors by developing a population-pharmacokinetic model to assess the pharmacokinetics of oxycodone and its metabolites in cancer patients, and to associate this with pain scores, and adverse events. Hospitalized patients with cancer-related pain, who were treated with oral oxycodone, could participate. Pharmacokine...
Source
#1Daan P. Hurkmans (EUR: Erasmus University Rotterdam)H-Index: 8
#2Sebastiaan D.T. Sassen (Erasmus University Medical Center)
Last. Stijn L.W. Koolen (EUR: Erasmus University Rotterdam)H-Index: 13
view all 15 authors...
BACKGROUND Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I-III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-world setting. METHODS Advanced-stage cancer patients, who were treated with pembrolizumab monotherapy (2 mg/kg Q3W or 200 mg flat Q3W), were prospectively included for serial sampling to obtain trough...
Source
Source
Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with 177Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter Ac-225. Higher efficacy is claimed due to high linear energy transfer specifically towards PSMA positive cells, causing more double-strand breaks. This study aims to manufacture [225Ac]Ac-PSMA-I&T according to good manufacturing practice guidelines ...
Source